RxDoctor Payments Data

Derek Kaznoski, MD

Gynecology · Martinsburg, WVNPI 1689675027

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Boston Scientific at 55.5% of the total. Reporting peaked in 2019 at $1,106 and has fallen 79.2% since, to $230 in 2025.

$1,640in general payments, 2019–2025

Across 36 payments — averaging $45.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$910
  • Astellas Pharma US Inc$560
  • ABC Home Medical Supply, Inc.$59
  • Therapeuticsmd, Inc.$50
  • GSK$17
  • Sumitomo Pharma America, Inc.$15
  • plus $29 from 2 others

What the payments were for

  • Travel & lodging$66040%
  • Food & beverage$78048%
  • Education$20012%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific6$910
Astellas Pharma US Inc21$560
ABC Home Medical Supply, Inc.1$59
Therapeuticsmd, Inc.4$50
GSK1$17
Sumitomo Pharma America, Inc.1$15
Medtronic1$15
BD1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$82,632
Medicare patients
241
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron38$40,363
Estradiol144$14,999
GemtesaVibegron11$11,545
Tolterodine Tartrate ErTolterodine Tartrate88$8,233
YuvafemEstradiol37$4,645
Trospium Chloride ErTrospium Chloride14$3,371
Oxybutynin Chloride ErOxybutynin Chloride128$2,028
Clobetasol Propionate39$1,157
Solifenacin Succinate23$903
Raloxifene Hcl16$559
Oxybutynin Chloride19$543
Ketoconazole27$477
Metronidazole20$453
Cephalexin50$435
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$560$40,36338 claims
Sumitomo Pharma America, Inc.Gemtesa$15$11,54511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other gynecology in Martinsburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →